세계의 비정형 용혈성 요독 증후군(aHUS) 치료 시장 보고서(2025년)

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening condition marked by abnormal blood clotting, which leads to damage in small blood vessels and results in hemolytic anemia, low platelet count, and kidney injury. It is often caused by genetic mutations or dysregulation in the complement system, leading to uncontrolled inflammation and vascular damage.

The main treatment options for atypical hemolytic uremic syndrome include complement inhibitors, plasma exchange therapy, supportive care, and antibiotics. Complement inhibitors are therapeutic agents that block or modulate the activation of the complement system, a critical component of the immune system involved in inflammation, immune response, and cell lysis. These inhibitors are administered through various routes, such as intravenous, subcutaneous, and oral. Technologies involved in the treatment include genetic testing and diagnostic tools, real-time monitoring and complement activation technologies, treatment delivery systems, and digital health solutions. These are used in various healthcare settings, including specialty clinics, home care environments, and ambulatory care centers.

The atypical hemolytic uremic syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides atypical hemolytic uremic syndrome treatment market statistics, including atypical hemolytic uremic syndrome treatment industry global market size, regional shares, competitors with atypical hemolytic uremic syndrome treatment market share, detailed atypical hemolytic uremic syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the atypical hemolytic uremic syndrome treatment industry. This atypical hemolytic uremic syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atypical hemolytic uremic syndrome treatment market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to several factors, including an increase in clinical trials, growing awareness of the disease, government support for research, enhanced diagnostic capabilities, and a rising incidence of the disease.

The atypical hemolytic uremic syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to factors such as government support initiatives, a focus on complement dysregulation, growing patient awareness, increased availability of treatments, and improved diagnostic techniques. Key trends in the forecast period include next-generation complement inhibitors, digital health monitoring and AI tools, AI-driven drug discovery, personalized medicine, and genotyping and biomarker-based diagnostics.

The increasing demand for targeted therapies is expected to drive the growth of the atypical hemolytic uremic syndrome (aHUS) treatment market. Targeted therapies are medical treatments that specifically focus on and disrupt the molecular pathways involved in disease progression. The growing demand for these therapies stems from their ability to deliver more precise treatments with fewer side effects, leading to improved patient outcomes and offering alternatives to traditional, broader treatments. In the case of atypical hemolytic uremic syndrome, targeted therapies work by blocking the overactivation of the complement system, which is the primary cause of the disease. This allows for precise interventions that reduce damage to blood vessels and kidneys. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England, a 47% increase from 2021-22, with approximately 2.3 million patients receiving prescriptions, marking a 29% year-on-year rise. Consequently, the increasing demand for targeted therapies is fueling the growth of the atypical hemolytic uremic syndrome treatment market.

Key players in the atypical hemolytic uremic syndrome treatment market are focusing on developing cutting-edge therapies, such as monoclonal antibody drugs, to enhance targeted complement inhibition and improve patient outcomes. Monoclonal antibodies are laboratory-engineered proteins that mimic the immune system's ability to combat harmful pathogens by specifically targeting and binding to certain proteins involved in disease mechanisms. For example, in January 2025, AstraZeneca Pharma India Limited, a biopharmaceutical company based in India, received approval from the Central Drugs Standard Control Organization (CDSCO) to import, sell, and distribute eculizumab (marketed as Soliris) in India. These monoclonal antibodies specifically bind to the complement protein C5, preventing its cleavage and thereby blocking the formation of the terminal complement complex responsible for immune-mediated cell damage. Eculizumab is used to treat rare and severe conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica spectrum disorder by preventing complement-mediated damage.

In October 2022, Amgen Inc., a US-based biotechnology company, acquired ChemoCentryx Inc. for approximately $3.7 billion. This acquisition is part of Amgen's strategy to expand its portfolio in the field of autoimmune and rare diseases by incorporating ChemoCentryx's innovative therapies and expertise in complement-based treatments. ChemoCentryx Inc., a US-based biopharmaceutical company, specializes in developing treatments for rare conditions, including atypical hemolytic uremic syndrome (aHUS).

Major players in the atypical hemolytic uremic syndrome treatment market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Alnylam Pharmaceuticals Inc., Vifor Pharma Ltd., Samsung Bioepis Co. Ltd., Fuji Pharma Co. Ltd., Aevitas Therapeutics Inc., Pharmasyntez JSC, Omeros Corporation, ChemoCentryx Inc., ISU Abxis Co. Ltd., Greenovation Biotech GmbH, Akari Therapeutics plc, NovelMed Therapeutics Inc., Eleva GmbH.

North America was the largest region in the atypical hemolytic uremic syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atypical hemolytic uremic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the atypical hemolytic uremic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atypical hemolytic uremic syndrome (aHUS) market consists of revenues earned by entities by providing services such as renal support and dialysis, genetic testing and counseling, long-term monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical hemolytic uremic syndrome (aHUS) market also includes sales of immunosuppressive therapies, plasma exchange equipment, dialysis machines, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atypical hemolytic uremic syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atypical hemolytic uremic syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atypical hemolytic uremic syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Complement Inhibitors; Plasma Exchange Therapy; Supportive Care; Antibiotics
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Technology: Genetic Testing And Diagnostic Tools; Realtime Monitoring And Complement Activation Technologies; Treatment Delivery Systems; Digital Health Solutions
• 4) By End User: Hospital; Speciality Clinics; Home care Settings; Ambulatory Care Centres
• Subsegments:
• 1) By Complement Inhibitors: Eculizumab; Ravulizumab; C5 Inhibitors; Factor H Inhibitors; Other Complement Inhibitors
• 2) By Plasma Exchange Therapy: Fresh Frozen Plasma (FFP) Exchange; Therapeutic Plasma Exchange (TPE); Plasma Filtration; Other Plasma Exchange Techniques
• 3) By Supportive Care: Dialysis; Kidney Transplantation; Red Blood Cell Transfusions; Platelet Transfusions; Anticoagulants; Other Supportive Therapies
• 4) By Antibiotics: Broad-Spectrum Antibiotics; Targeted Antibiotics; Prophylactic Antibiotics; Other Antibiotic Treatments
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atypical Hemolytic Uremic Syndrome Treatment Market Characteristics

3. Atypical Hemolytic Uremic Syndrome Treatment Market Trends And Strategies

4. Atypical Hemolytic Uremic Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Atypical Hemolytic Uremic Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Atypical Hemolytic Uremic Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Atypical Hemolytic Uremic Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Atypical Hemolytic Uremic Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Atypical Hemolytic Uremic Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Atypical Hemolytic Uremic Syndrome Treatment Total Addressable Market (TAM)

6. Atypical Hemolytic Uremic Syndrome Treatment Market Segmentation

• 6.1. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complement Inhibitors
• Plasma Exchange Therapy
• Supportive Care
• Antibiotics
• 6.2. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing And Diagnostic Tools
• Realtime Monitoring And Complement Activation Technologies
• Treatment Delivery Systems
• Digital Health Solutions
• 6.4. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Speciality Clinics
• Home care Settings
• Ambulatory Care Centres
• 6.5. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eculizumab
• Ravulizumab
• C5 Inhibitors
• Factor H Inhibitors
• Other Complement Inhibitors
• 6.6. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Plasma Exchange Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fresh Frozen Plasma (FFP) Exchange
• Therapeutic Plasma Exchange (TPE)
• Plasma Filtration
• Other Plasma Exchange Techniques
• 6.7. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dialysis
• Kidney Transplantation
• Red Blood Cell Transfusions
• Platelet Transfusions
• Anticoagulants
• Other Supportive Therapies
• 6.8. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Targeted Antibiotics
• Prophylactic Antibiotics
• Other Antibiotic Treatments

7. Atypical Hemolytic Uremic Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market

• 8.1. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Atypical Hemolytic Uremic Syndrome Treatment Market

• 9.1. China Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 9.2. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Atypical Hemolytic Uremic Syndrome Treatment Market

• 10.1. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Atypical Hemolytic Uremic Syndrome Treatment Market

• 11.1. Japan Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 11.2. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Atypical Hemolytic Uremic Syndrome Treatment Market

• 12.1. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market

• 13.1. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market

• 14.1. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 14.2. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market

• 15.1. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 15.2. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Atypical Hemolytic Uremic Syndrome Treatment Market

• 16.1. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Atypical Hemolytic Uremic Syndrome Treatment Market

• 17.1. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Atypical Hemolytic Uremic Syndrome Treatment Market

• 18.1. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Atypical Hemolytic Uremic Syndrome Treatment Market

• 19.1. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Atypical Hemolytic Uremic Syndrome Treatment Market

• 20.1. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market

• 21.1. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 21.2. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Atypical Hemolytic Uremic Syndrome Treatment Market

• 22.1. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Atypical Hemolytic Uremic Syndrome Treatment Market

• 23.1. North America Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 23.2. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Atypical Hemolytic Uremic Syndrome Treatment Market

• 24.1. USA Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 24.2. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Atypical Hemolytic Uremic Syndrome Treatment Market

• 25.1. Canada Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 25.2. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Atypical Hemolytic Uremic Syndrome Treatment Market

• 26.1. South America Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 26.2. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market

• 27.1. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market

• 28.1. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 28.2. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Atypical Hemolytic Uremic Syndrome Treatment Market

• 29.1. Africa Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 29.2. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape
• 30.2. Atypical Hemolytic Uremic Syndrome Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Atypical Hemolytic Uremic Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Chugai Pharmaceutical Co. Ltd.
• 31.3. Alnylam Pharmaceuticals Inc.
• 31.4. Vifor Pharma Ltd.
• 31.5. Samsung Bioepis Co. Ltd.
• 31.6. Fuji Pharma Co. Ltd.
• 31.7. Aevitas Therapeutics Inc.
• 31.8. Pharmasyntez JSC
• 31.9. Omeros Corporation
• 31.10. ChemoCentryx Inc.
• 31.11. ISU Abxis Co. Ltd.
• 31.12. Greenovation Biotech GmbH
• 31.13. Akari Therapeutics plc
• 31.14. NovelMed Therapeutics Inc.
• 31.15. Eleva GmbH

32. Global Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atypical Hemolytic Uremic Syndrome Treatment Market

34. Recent Developments In The Atypical Hemolytic Uremic Syndrome Treatment Market

35. Atypical Hemolytic Uremic Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer